The potential role of tomudex in the treatment of advanced colorectal cancer

Tumori

Volumn 83, Issue 2, 1997, Pages 576-580

  Sobrero, Alberto F ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Colorectal cancer; Tomudex

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; RALTITREXED;

ADVANCED CANCER; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION;

EID: 0030787765     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300220     Document Type: Conference Paper

References (42)

1. Ardalan B., Chua L., Tian E.: A phase II study of weekly 24 hour infusion with high dose 5-fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol., 9: 625-630, 1991.
2. Armand J.P., Ducreux M., Mahjoubyi M.: CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer, 31 A: 1283-1287, 1995.
3. Aschele C., Baldo C., Guglielmi A. Sobrero A.: Sequence dependent synergism between Tomudex and Irinotecan in human colon cancer cells in vitro. 9th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, March 12-15, 1996 (abstr 302).
4. Chang Y.M., Aschele C., Sobrero A. Faderan M., Bertino J.R.: Sensitivity of two fluorouracil resistant HCT-8 cell lines to fluorouridine ( FUR), methotrexate (MTX) and D 1694, a folate inhibitor of thymidylate synthase. Proc. Am. Assoc. Cancer Res., 33: 543 (abstr 3248), 1992.
5. Chang Y.M., Zielinski Z., Izzo J.: Pretreatment of human colon carcinoma cells to DI1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc. Am. Assoc. Cancer Res., 330 (abstr 1966), 1994.
6. Clarke S., Ward. J., Planting A.: Phase I trial of ICI D 1694: a novel thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 33 (abstr 2426), 1992.
7. Conti J.A., Kemeny N., Saltz L.B. Bertino J.R.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin.. Oncol., 14: 709-715, 1996.
8. Cunningham D., Zalcberg J.R., Rath U., Van Cutsem: 'Tomudex' (ZD 1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leukopenia. Eur. J. Cancer, 31 A: 1945-1954, 1995.
9. Ehrlichman C., Fine S., Wong A.: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 6: 469-475, 1988.
10. Fuchs C.S., Mayer R.J.: Colorectal cancer chemotherapy. In: Gastrointestinal cancers: biology, diagnosis and therapy, Rustgy A.K., Ed., pp. 423-442, Lippincott-Raven, Philadelphia, 1995,
11. Gibson W., Bisset G.M., Marsham P.R.: The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor ICI D 1694, in mouse and human cultured cells. Biochem. Pharmacol., 45: 863-869, 1993.
12. Guimaraes M.A., Greco W.R., Slocum H.K., Pavelic C.: The combined action of ICI D 1694 , 5́ fluorodeoxyuridine and 5-fluororuracil in inhibiting the growth of human renal cell carcinoma cell line (RPMI-SE) in vitro. Int. J. Oncol., 4: 137-141, 1994.
13. Izzo J., Zielinsky Z., Chang Y., Bertino J.R.: Molecular mechanism of the synergistic sequential administration of D 1694 (Tomudex) followed by FUra in colon carcinoma cells. Proc. Amer. Ass. Cancer Res., 36: 381 (abstr 2272), 1985.
14. Jackman A.L., Farrugia D.C., Gibson W.: ZD 1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31 A: 1277-1282, 1995
15. Jackman A.L., Taylor G.A., Gibson W.: ICI DI 1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
16. Johnstone P., Behan K., Allegra C.: Fluorouracil: active in ZD 1694 (Tomudex) resistant cell lines with markedly elevated thymidylate synthase levels. J. Natl. Cancer Inst., 87: 1558-1559, 1995.
17. Judson I., Clarke S., Ward J.: Pharmacokinetics of ICI D 1694 following a 15 min infusion in patients with advanced cancer. Proc. Amer. Soc. Clin. Oncol., 11 (abstr. 288), 1992.
18. Kemeny N: Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J. Clin. Oncol., 13: 1287-1290, 1995
19. Laurie J.A., Moertel C.G., Fleming T.R.: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol., 7: 1447-1456, 1989.
20. Leichman C.G., Fleming T.L., Muggia F.M., Mc Donald J.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a South-West Oncology Group study. J. Clin. Oncol., 13: 1303-1312, 1995.
21. Mamounas E.P., Rockette H., Jones J., Wolmark N.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer from NSABP adjuvant studies. Proc. Am. Soc. Clin. Oncol., 15: 205 (abstr. 461), 1966.
22. Marsh J.C., Bertino J.R., Davis C.A.: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol., 9: 371-380, 1991.
23. Marsham P.R., Hughes L.R., Jackman A.: Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J. Medicine Chem., 34: 1594-1605, 1991.
24. Moertel C.G., Fleming T.R., Macdonald J.S.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
25. Moller J., Esteve J., Moller H., Renard H.: Cancer in the European Community and its member states. Eur. J. Cancer, 26: 1167-1256, 1990.
26. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol., 10: 904-911, 1992.
27. Petrelli N.J.: It is time to stratify with prognostic factors for hepatic metastases. J. Clin. Oncol., 13: 2471-2472, 1995.
28. Petrelli N., Douglass O.H. Jr, Herrera L., Rustum J.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol., 7: 1419-1426, 1989.
29. Poon M.A., O'Connel M.J., Moertel C.G.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 7: 1407-1408, 1989.
30. Pressacco J., Erlichman C.: Combination studies with 3′-azido-3′ deoxythymidine (AZT) plus ICI D 1694. Cytotoxic and biochemical effects. Biochem. Pharmacol., 46: 1989-1997, 1993.
31. Pressacco J., Medley D.V., Erlichman C.: ICI D 1694 and idoxuridine: a synergistic antitumor combination. Cancer Res., 54: 3772-3778, 1994
32. Pressacco J., Lewis K.J., Mitrowsky B.: Biochemical modulation of ara C by D 1694 in the human bladder cancer cell line MGH-U1. Can. J. Physiol. Pharmacol., 72 (abstr. P2.2.28), 1994
33. Rothenberg M., Eckardt J., Kuhn J.: Phase II trial of Irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol., 14: 1128-1135, 1996.
34. Seitz J.F., Cunningham D., Rath U.: Final results and survival data of a large randomized trial of Tomudex in advanced colorectal cancer confirm comparable efficacy to 5-fluorouracil + leucovorin. Proc. Am. Soc. Clin. Oncol., 15: 201 (abstr. 446), 1966.
35. Shimada Y., Yoshino M., Wakui A.: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
36. Sobrero A.F., Aschele C., Bertino J.R.: Five fluorouracil bolus and continuous infusion: a tale of two drugs. Implications for biochemical modulation in colorectal cancer. J. Clin. Oncol., in press.
37. Sobrero A., Aschele C., Guglielmi A., Mori A., Bertino J.: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst., 85: 1937-1944, 1993.
38. Sorensen J.M., Jordan E., Green J.L.: Phase I trial of ZD 1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann. Oncol. 5 ( suppl. 5): 1994.
39. Tuoroutoglu N., Pazdur R.: Thymidylate synthase inhibitors. Clin. Cancer Res., 2: 227-243, 1996.
40. Wolmark N., Rockette H., Fisher B.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J. Clin. Oncol., 11: 1879-1887, 1993.
41. Yin M.B., Guimaraes M.A., Zhang Z.G.: Time dependence of DNA lesions and growth inhibition by ICI D 1694 , a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res., 52: 5900-5905, 1992.
42. Zalcberg J.R., Cunningham D., Van Cutsem E.: ZD 1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.